US Food and Drug Administration Approval of Aducanumab—Is Amyloid Load a Valid Surrogate End Point for Alzheimer Disease Clinical Trials?
Vincent Planche, Nicolas Villain
JAMA Neurol. 2021-09-13; :
DOI: 10.1001/jamaneurol.2021.3126
![PubMed](https://www.bordeaux-neurocampus.fr/wp-content/uploads/2019/01/logoPubMed.png)
Read on PubMed
JAMA Neurol. 2021-09-13; :
DOI: 10.1001/jamaneurol.2021.3126
![PubMed](https://www.bordeaux-neurocampus.fr/wp-content/uploads/2019/01/logoPubMed.png)
Read on PubMed
Planche V(1)(2), Villain N(3)(4).
Author information:
(1)University of Bordeaux, CNRS, IMN, UMR 5293, Bordeaux, France.
(2)Centre Mémoire Ressources Recherches, Pôle de Neurosciences Cliniques, CHU de
Bordeaux, Bordeaux, France.
(3)AP-HP Sorbonne Université, Hôpital Pitié-Salpêtrière, Department of Neurology,
Institute of Memory and Alzheimer’s Disease, Paris, France.
(4)Institut du Cerveau – ICM, Sorbonne Université, INSERM U1127, CNRS 7225,
Paris, France.